Safety and Dosing Study of Glucagon‐Like Peptide 2 in Children With Intestinal Failure

Abstract

GLP-2 was well tolerated in children, with a pharmacokinetic profile similar to that of adults. There were no changes in endogenous GLP-2 release or metabolism. These results suggest that GLP-2 ligands may be safely used in pediatric patients; larger trials are suggested to investigate nutritional effects.